Heterogeneity of systemic lupus erythematosus (SLE) remains challenging and, thus, many unmet needs remain, including the development of safer and more efficacious therapies to better control SLE activity resulting in improved outcomes. To develop innovative therapies, we need a far better understanding of its pathogenesis including delineation of clinical phenotypes. Recently, the the lupus community has developed new classification criteria, T2T principles as well as low lupus disease activity and remission definitions to overcome obstacles created by SLE heterogeneity and improve outcomes. New proposals for the histologic classification of lupus nephritis have also been put forward and undergo evaluation. Recent therapeutic advances and clinical developments hold promise for improved treatments in this challenging disease and will be discussed.

Disclosure of Interests: Thomas Dörner Grant/research support from: Eli Lilly, Janssen, Roche, UCB Pharma, Consultant for: Eli Lilly, Janssen, Roche, UCB Pharma, Speakers bureau: Eli Lilly, Janssen

DOI: 10.1136/annrheumdis-2019-eular.8461